

Docket No.: 1686-0108P

(PATENT)

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Yoko MOTODA et al.

Application No.: 10/748,055 Confirmation No.: 8334

Filed: December 31, 2003 Art Unit: 1636

For: METHOD OF PRODUCING TEMPLATE DNA

AND METHOD OF PRODUCING PROTEIN IN CELL-FREE PROTEIN SYNTHESIS

SYSTEM USING THE SAME

Examiner: R. Akhavan

## INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FINAL REJECTION)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

#### I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

#### II. COPIES

Copies of cited U.S. patents and patent application publications are not included. <u>Copies</u> of foreign patent documents and non-patent literature are included.

Birch, Stewart, Kolasch & Birch, LLP

Application No.: 10/748,055 Docket No.: 1686-0108P

### III. CONCISE EXPLANATION OF THE RELEVANCE (Check at least one box) $\boxtimes$ DOCUMENTS IN THE ENGLISH LANGUAGE - The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the b. relevance of all patents, publications, or other information listed that is not in the English language is as follows: ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search X report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3). OTHER - The following additional information is provided for the Examiner's d. consideration. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(d): After the mailing date of a Final Action under § 1.113. See the Statement Under 37 C.F.R. § 1.97(e). IV. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box) The undersigned hereby states that: Each item of information contained in the IDS was first cited in any

communication from a foreign Patent Office in a counterpart foreign application not more

than 30 days prior to the filing of this IDS; or

Application No.: 10/748,055 Docket No.: 1686-0108P

b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

- No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- Detent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

### V. <u>PAYMENT OF FEES</u> (check one box)

The required fee is listed on the attached Fee Transmittal.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for

Application No.: 10/748,055 Docket No.: 1686-0108P

any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: November 14, 2005

Respectfully submitted,

Mark J. Nuell, Ph.D.

Registration No.: 36,623

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

Attachment(s):

$\boxtimes$	PTO-SB08
<u> </u>	_

Documents

Foreign Search Report

⊠ Fee

Other: Fee Transmittal



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE oct of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known				
Application Number	10/748,055-Conf. #8334			
Filing Date	December 31, 2003			
First Named Inventor	Yoko MOTODA			
Art Unit	1636			
Examiner Name	R. Akhavan			
Attorney Docket Number	1686-0108P			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	ВА	EP-1 316 616-A1	06-04-2003	ROCHE DIAGNOSTICS GmbH		7		
	ВВ	WO-00/56914-A1	09-28-2000	GENE THERAPY SYSTEMS, INC		1		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>					
	CA	KAIN, et al.; "UNIVERSAL PROMOTER FOR GENE EXPRESSION WITHOUT CLONING: EXPRESSION-PCR"; BioTechniques; Vol. 10, No. 3; March 1991; pages 366-368 and 370; XP-000912135.				
	СВ	MACFERRIN, et al.; "OVERPRODUCTION AND DISSECTION OF PROTEINS BY THE EXPRESSION-CASSETTE POLYMERASE CHAIN REACTION"; Proceedings of the National Academy of Sciences of the USA; March 1, 1990; Vol. 87, No. 5; pages 1937-1941; XP000268593				
	CC	OHUCHI, et al.; "IN VITRO METHOD FOR THE GENERATION OF PROTEIN LIBRARIES USING PCR AMPLIFICATION OF A SINGLE DNA MOLECULE AND COUPLED TRANSCRIPTION/TRANSLATION"; Nucleic Acids Research; October, 1998; Vol. 26, No. 19; pages 4339-4346; XP-002119037.				
	CD	NAKANO, et al.; "EFFICIENT COUPLED TRANSCRIPTION/TRANSLATION FROM PCR TEMPLATE BY A HOLLOW-FIBER MEMBRANE BIOREACTOR"; Biotechnology and Bioengineering, Interscience Publishers; July 20, 1999; XP-001084028; pages 194-199.				
	CE	SANDHU, et al.; "DUAL ASYMMETRIC PCR: ONE-STEP CONSTRUCTION OF SYNTHETIC GENES"; Biotechniques; Vol. 12, No. 1; 1992; XP-002134139; pages 14-16.				
	CF	GE, et al.; "SIMULTANEOUS INTRODUCTION OF MULTIPLE MUTATIONS USING OVERLAP EXTENSION PCR"Biotechniques, Vol., 22, No. 1, January 1997; XP-000676361; pages 28 and 30.				
	CG	HORTON, et al.; "ENGINEERING HYBRID GENES WITHOUT THE USE OF RESTRICTION ENZYMES: GENE SPLICING BY OVERLAP EXTENSION"; GEne, Elsevier Biomedical Press; Vol. 77; April 15, 1989; pages 61-68; XP-002090392.				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Date Considered
	DDN//ob

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/17 (12-04v2)

Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number Complete if Known Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). 10/748,055-Conf. #8334 Application Number RANSMITTAL Filing Date December 31, 2003 Yoko MOTODA First Named Inventor For FY 2005 NOV 1 4 2005 Examiner Name R. Akhavan 1636 Applicant claims small entity status. See 37 CFR 1.27 Art Unit 1686-0108P TOTAL AMOUNT OF PAYMENT 180.00 Attorney Docket No. METHOD OF PAYMENT (check all that apply) Check None Credit Card Money Order Other (please identify): Deposit Account Number: 02-2448 Deposit Account Name: Birch, Stewart, Kolasch & Birch, LLP For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or underpayment of Credit any overpayments fee(s) under 37 CFR 1.16 and 1.17 **FEE CALCULATION** 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES SEARCH FEES EXAMINATION FEES** Small Entity **Small Entity** Small Entity **Application Type** Fee (\$) Fee (\$) Fee (\$) Fees Paid (\$) Fee (\$) Fee (\$) Fee (\$) 200 Utility 300 150 500 250 100 Design 200 100 100 50 130 65 200 100 300 150 160 80 Plant 300 500 250 600 Reissue 150 300 200 100 0 Provisional 0 0 2. EXCESS CLAIM FEES **Small Entity** Fee (\$) Fee (\$) Fee Description Each claim over 20 (including Reissues) 50 25 Each independent claim over 3 (including Reissues) 200 100 Multiple dependent claims 360 180 Multiple Dependent Claims **Total Claims** Extra Claims Fee Paid (\$) Fee (\$) Fee Paid (\$) Fee Paid (\$) Fee (\$) Indep. Claims Extra Claims - 3 = 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Fee Paid (\$) **Total Sheets** Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) - 100 = (round up to a whole number) x 4. OTHER FEE(S) Fees Paid (\$) Non-English Specification, \$130 fee (no small entity discount) Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00

SUBMITTED BY					
Signature	MNICH	Registration No. (Attorney/Agent)	36,623	Telephone	(703) 205-8043
Name (Print/Type)	Markຝ໌. Nuell, Ph.D.			Date	November 14, 2005